Wedbush analyst, David Nierengarten, is cautious on Ironwood Pharmaceuticals (NASDAQ: IRWD) as operating leverage remains elusive. No change to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE